The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T cells. To evade immune eradication, cancers exploit checkpoints that dampen T cell reactivity. Immune checkpoint inhibitors (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer cell 2021-02, Vol.39 (2), p.154-173
Hauptverfasser:	Jardim, Denis L., Goodman, Aaron, de Melo Gagliato, Debora, Kurzrock, Razelle
Format:	Artikel
Sprache:	eng
Schlagworte:	biomarker Biomarkers, Tumor - genetics Biomarkers, Tumor - immunology cancer therapy genetics Humans Immune Checkpoint Inhibitors - pharmacology immunotherapy Immunotherapy - methods Major Histocompatibility Complex - genetics Major Histocompatibility Complex - immunology Mutation - genetics Mutation - immunology mutattional load Neoplasms - genetics Neoplasms - immunology Neoplasms - therapy T-Lymphocytes - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!